Name | TMPH |
Description | TMPH is an inhibitor of nAChR and inhibits nAChRs lacking α5, α6, or β3 subunits. TMPH can be used in studies about nAChR dysfunction or neurological disorders. |
In vitro | TMPH (100 nM) inhibits nAChR with an inhibition rate of 90% in Xenopus oocytes and suppresses AChR subtypes with IC50s of 1.0-390 nM[1]. |
In vivo | In the nicotine-induced mice model, nAChR-IN-1 (20 mg/kg; s.c.) increases locomotor activity without effects on body temperature. In the tail-flick and hot-plate mice model, nAChR-IN-1(0, 0.1, 1, 5 mg/kg; s.c.) blocks the antinociceptive effect of nicotine in the hot-plate and blocks antinociception in a time-dependent manner[1]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 50 mg/mL (185.58 mM)
|
Keywords | neurol disorder | nAChR | Nicotinic acetylcholine receptors | neuronal nicotinic receptors | TMPH | selective inhibition | Inhibitor | inhibit | nicotinic receptor | brain function | tetramethylpiperidinyl heptanoate | 2,2,6,6-Tetramethylpiperidin-4-yl Heptanoate | dysfunction |
Inhibitors Related | Adiphenine hydrochloride | Nanofin | Arecoline hydrobromide | Forskolin | Pilocarpine Hydrochloride | CLOZAPINE N-OXIDE | Pilocarpine nitrate | Ribavirin | Adenine | Amitriptyline hydrochloride | Choline chloride | Propoxur |
Related Compound Libraries | Bioactive Compound Library | Pain-Related Compound Library | Anti-Neurodegenerative Disease Compound Library | Neuronal Signaling Compound Library | Membrane Protein-targeted Compound Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Bioactive Compounds Library Max |